Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Exicure Inc (XCUR) USD0.0001

Sell:$2.16 Buy:$2.50 Change: $0.04 (1.76%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$2.16
Buy:$2.50
Change: $0.04 (1.76%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$2.16
Buy:$2.50
Change: $0.04 (1.76%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).

Contact details

Address:
2430 N. HALSTED ST.
CHICAGO
60614
United States
Telephone:
+1 (847) 6731700
Website:
www.exicuretx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XCUR
ISIN:
US30205M1018
Market cap:
$191.03 million
Shares in issue:
87.23 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Timothy Walbert
    Independent Chairman of the Board
  • David Giljohann
    Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director
  • Matthias Schroff
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.